~~<i id='69C8D20096'><strike id='69C8D20096'><tt id='69C8D20096'><pre id='69C8D20096'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

entertainment

author：comprehensive 2025-09-06 02:11:31 - browse：7

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

hotspot

focus

hotspot

explore

focus

VictoriaAzarenkaofBelarusplaysareturntoChina'sYuanYueduringthefirstroundwomen'ssinglesmatchondayoneo

WSS

Noem? Reynolds? A very early look at the Republican 'veepstakes'

Weight loss drugs aren’t covered by Obamacare. That may change

FDA warns medical device makers about rise in fabricated data

Some in Scotland's Orkney Islands want to return to Norway after 550 years

3 killed, 8 injured in late

A timeline of the missing Titanic tourist submersible

hotspot

entertainment

hotspot

Sports medicine is finally prioritizing gender equality

Palestinian attacker wounds 8 in Tel Aviv as Israel presses on with West Bank operation

Tori Bowie and the unacceptable rates of Black maternal death

Weight loss drugs aren’t covered by Obamacare. That may change

Cancer drug shortages should be causing more outrage

Elon Musk announces 'temporary limits' for reading Twitter posts

Heart attack and stroke risk calculators need revising

Brazil's Neymar fined $3.3 million for illegal artificial lake at mansion outside Rio

Alkermes shareholders re

Opioid cravings were reduced by anti

focus

Flagship Pioneering startup Sonata Therapeutics lays off 21

MD Anderson's Padmanee Sharma responds to research credit suit

EU climate chief is concerned over the expansion of the coal industry in China

FDA warns medical device makers about rise in fabricated data

EU climate chief is concerned over the expansion of the coal industry in China

Churchill Downs extends trainer Bob Baffert's ban through 2024

hotspot

hotspot

explore

focus